Patient and treatment factors associated with complications after prostate brachytherapy

Journal of Clinical Oncology

Volumn 24, Issue 33, 2006, Pages 5298-5304

  Chen, Aileen B ^a   D'Amico, Anthony V ^a   Neville, Bridget A ^a   Earle, Craig C ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; BLEEDING; BRACHYTHERAPY; CANCER EPIDEMIOLOGY; CANCER REGISTRY; CONTROLLED STUDY; ERECTILE DYSFUNCTION; EXTERNAL BEAM RADIOTHERAPY; HUMAN; INVASIVE PROCEDURE; MAJOR CLINICAL STUDY; MALE; MEDICARE; PATIENT ATTITUDE; PREVALENCE; PRIORITY JOURNAL; PROCTITIS; PROSTATE CANCER; SCORING SYSTEM; TREATMENT OUTCOME; COMORBIDITY; DEFECATION; MICTURITION; MICTURITION DISORDER; PENIS ERECTION; PREDICTION AND FORECASTING; PROSTATE TUMOR; RADIATION EXPOSURE; RISK; RISK FACTOR; STATISTICAL MODEL;

AGED; AGED, 80 AND OVER; BRACHYTHERAPY; COMORBIDITY; DEFECATION; HUMANS; LOGISTIC MODELS; MALE; ODDS RATIO; PENILE ERECTION; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROSTATIC NEOPLASMS; RISK FACTORS; URINATION; URINATION DISORDERS;

EID: 34247383108     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.07.9954     Document Type: Article

References (37)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2006. CA Cancer J Clin 56:106-130, 2006
2. Blasko JC, Grimm PD, Sylvester JE, et al: Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 46:839-850, 2000
3. Ragde H, Elgamal AA, Snow PB, et al: Tenyear disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer 83: 989-1001, 1998
4. D'Amico AV, Whittington R, Malkowicz SB, et al: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969-974, 1998
5. Sylvester JE, Blasko JC, Grimm PD: Brachytherapy as monotherapy, in Kantoff PW, Carroll PR, Damico AV (eds): Prostate cancer: Principles and Practice (ed 1). Philadelphia, PA, Lippincott Williams & Wilkins, 2002, pp 336-357
6. Lee WR, Moughan J, Owen JB, et al: The 1999 patterns of care study of radiotherapy in localized prostate carcinoma: A comprehensive survey of prostate brachytherapy in the United States. Cancer 98:1987-1994, 2003
7. Mettlin CJ, Murphy GP, McDonald CJ, et al: The National Cancer database report on increased use of brachytherapy for the treatment of patients with prostate carcinoma in the US. Cancer 86:1877-1882, 1999
8. Brandeis J, Pashos CL, Henning JM, et al: A nationwide charge comparison of the principal treatments for early stage prostate carcinoma. Cancer 89:1792-1799, 2000
9. Cooperberg MR, Lubeck DP, Meng MV, et al: The changing face of low-risk prostate cancer: Trends in clinical presentation and primary management. J Clin Oncol 22:2141-2219, 2004
10. Edwards BK, Brown ML, Wingo PA, et al: Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97:1407-1427, 2005
11. Harlan LC, Potosky A, Gilliland FD, et al: Factors associated with initial therapy for clinically localized prostate cancer: Prostate cancer outcomes study. J Natl Cancer Inst 93:1864-1871, 2001
12. Blasko JC, Ragde H, Grimm PD: Transperineal ultrasound-guided implantation of the prostate: Morbidity and complications. Scand J Urol Nephrol Suppl 137:113-118, 1991
13. Gelblum DY, Potters L, Ashley R, et al: Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys 45:59-67, 1999
14. Gelblum DY, Potters L: Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 48:119-124, 2000
15. Sarosdy MF: Urinary and rectal complications of contemporary permanent transperineal brachytherapy for prostate carcinoma with or without external beam radiation therapy. Cancer 101:754-760, 2004
16. Zippin C, Lum D, Hankey BF: Completeness of hospital cancer case reporting from the SEER Program of the National Cancer Institute. Cancer 76:2343-2350, 1995
17. Nattinger AB, McAuliffe TL, Schapira MM: Generalizability of the surveillance, epidemiology, and end results registry population: Factors relevant to epidemiologic and health care research. J Clin Epidemiol 50:939-945, 1997
18. Potosky AL, Riley GF, Lubitz JD, et al: Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 31:732-748, 1993
19. Greene FL, American Joint Committee on Cancer, American Cancer Society: AJCC Cancer Staging Handbook, in AJCC Cancer Staging Manual (ed 6). New York, NY, Springer, 2002
20. Bach PB, Guadagnoli E, Schrag D, et al: Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care 40:IV-19-25, 2002
21. Oleynick JU, Albertsen PC, Barry MM, et al: Utility of the SEER-Medicare data to identify medical androgen deprivation therapy. J Clin Oncol 24:328s, 2006 (suppl; abstr 6113)
22. Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45:613-619, 1992
23. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40:373-383, 1987
24. Klabunde CN, Potosky AL, Legler JM, et al: Development of a comorbidity index using physician claims data. J Clin Epidemiol 53:1258-1267, 2000
25. Ragde H, Blasko JC, Grimm PD, et al: Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. Cancer 80:442-453, 1997
26. Stock RG, Stone NN, DeWyngaert JK, et al: Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma. Cancer 77:2386-2392, 1996
27. Kang SK, Chou RH, Dodge RK, et al: Gastrointestinal toxicity of transperineal interstitial prostate brachytherapy. Int J Radiat Oncol Biol Phys 53:99-103, 2002
28. Feigenberg SJ, Lee WR, Desilvio ML, et: Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05. Int J Radiat Oncol Biol Phys 62:956-964, 2005
29. Macdonald AG, Keyes M, Kruk A, et al: Predictive factors for erectile dysfunction in men with prostate cancer after brachytherapy: Is dose to the penile bulb important? Int J Radiat Oncol Biol Phys 63:155-163, 2005
30. Merrick GS, Butler WM, Wallner KE, et al: Erectile function after prostate brachytherapy. Int J Radiat Oncol Biol Phys 62:437-447, 2005
31. Stock RG, Kao J, Stone NN: Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer. J Urol 165: 436-439, 2001
32. Benoit RM, Naslund MJ, Cohen JK: Complications after prostate brachytherapy in the Medicare population. Urology 55:91-96, 2000
33. Crook JM, Potters L, Stock RG, et al: Critical organ dosimetry in permanent seed prostate brachytherapy: Defining the organs at risk. Brachytherapy 4:186-194, 2005
34. Merrick GS, Wallner KE, Butler WM: Minimizing prostate brachytherapy-related morbidity. Urology 62:786-792, 2003
35. Willett CG, Ooi CJ, Zietman AL, et al: Acute and late toxicity of patients with inflammatory bowel disease undergoing irradiation for abdominal and pelvic neoplasms. Int J Radiat Oncol Biol Phys 46:995-998, 2000
36. Grann A, Wallner K: Prostate brachytherapy in patients with inflammatory bowel disease. Int J Radiat Oncol Biol Phys 40:135-138, 1998
37. Litwin MS, Lubeck DP, Henning JM, et al: Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: Results of the CaPSURE database. J Urol 159:1988-1992, 1998